Pasar al contenido principal

PAPEL DE LAS PROTEINAS DE LA FAMILIA UBICUITINA EN SEÑALIZACION, PROLIFERACION Y CANCER

SAF2017-90900-REDT

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Redes Investigación /Redes Excelencia
Año convocatoria 2017
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

SUMOylation modulates eIF5A activities in both yeast and pancreatic ductal adenocarcinoma cells

  • Seoane, Rocío
  • Lama-Díaz, Tomás
  • Romero, Antonia María
  • El Motiam, Ahmed
  • Vidal, Santiago
  • Bouzaher, Yanis H.
  • Blanquer, María
  • Tolosa, Rocío M.
  • Castillo Mewa, Juan
  • Rodríguez, Manuel S.
  • García-Sastre, Adolfo
  • Xirodimas, Dimitris
  • Sutherland, James D.
  • Barrio, Rosa
  • Alepuz, Paula
  • Blanco, Miguel G.
  • Farràs, Rosa
  • Rivas, Carmen
  • Martínez-Férriz, Arantxa|||0000-0001-7193-2575
[EN] BackgroundThe eukaryotic translation initiation protein eIF5A is a highly conserved and essential factor that plays a critical role in different physiological and pathological processes including stress response and cancer. Different proteomic studies suggest that eIF5A may be a small ubiquitin-like modifier (SUMO) substrate, but whether eIF5A is indeed SUMOylated and how relevant is this modification for eIF5A activities are still unknown.MethodsSUMOylation was evaluated using in vitro SUMOylation assays, Histidine-tagged proteins purification from His6-SUMO2 transfected cells, and isolation of endogenously SUMOylated proteins using SUMO-binding entities (SUBES). Mutants were engineered by site-directed mutagenesis. Protein stability was measured by a cycloheximide chase assay. Protein localization was determined using immunofluorescence and cellular fractionation assays. The ability of eIF5A1 constructs to complement the growth of Saccharomyces cerevisiae strains harboring thermosensitive mutants of a yeast EIF5A homolog gene (HYP2) was analyzed. The polysome profile and the formation of stress granules in cells expressing Pab1-GFP (a stress granule marker) by immunofluorescence were determined in yeast cells subjected to heat shock. Cell growth and migration of pancreatic ductal adenocarcinoma PANC-1 cells overexpressing different eIF5A1 constructs were evaluated using crystal violet staining and transwell inserts, respectively. Statistical analysis was performed with GraphPad Software, using unpaired Student's t-test, or one-way or two-way analysis of variance (ANOVA).ResultsWe found that eIF5A is modified by SUMO2 in vitro, in transfected cells and under endogenous conditions, revealing its physiological relevance. We identified several SUMO sites in eIF5A and found that SUMOylation modulates both the stability and the localization of eIF5A in mammalian cells. Interestingly, the SUMOylation of eIF5A responds to specific stresses, indicating that it is a regulated process. SUMOylation of eIF5A is conserved in yeast, the eIF5A SUMOylation mutants are unable to completely suppress the defects of HYP2 mutants, and SUMOylation of eIF5A is important for both stress granules formation and disassembly of polysomes induced by heat-shock. Moreover, mutation of the SUMOylation sites in eIF5A abolishes its promigratory and proproliferative activities in PANC-1 cells.ConclusionsSUMO2 conjugation to eIF5A is a stress-induced response implicated in the adaptation of yeast cells to heat-shock stress and required to promote the growth and migration of pancreatic ductal adenocarcinoma cells., Open Access funding was provided thanks to the CRUE-CSIC agreement with Springer Nature. Funding at the laboratory of CR is provided by the Ministry of Science, Innovation and Universities and FEDER (BFU-2017-88880-P, PID2021-126510NBI00), and by the Xunta de Galicia (ED431G 2023/10). RS, SV and TLD are predoctoral fellows funded by the Xunta de Galicia – Consellería de Cultura, Educación y Ordenación Universitaria (ED481A-2020/160, ED481A-2018/110, and ED481A-2018/042, respectively). AMR is a postdoctoral fellow funded by the Generalitat Valenciana (CIAPOS2021/117). MB is a predoctoral fellow funded by Banco Santander and the University of Santiago de Compostela. RMT is a predoctoral fellow funded by the Instituto de Investigación Sanitaria de Santiago de Compostela. The Blanco lab is supported by MCIN/AEI/https://doi.org/10.13039/501100011033 (PID2020-115472GB-I00) and by the Xunta de Galicia/FEDER – Una manera de hacer Europa (ED431C 2019/013). The RF lab is supported by the Fondo de Investigación Sanitaria, ISCIII (PI20-00194). The PA lab is supported by MCIN/AEI/https://doi.org/10.13039/501100011033 (PID2020-120066RB-I00) and by GVA CIAICO/2022/237. AMF is a predoctoral fellow funded by the Asociación Española Contra el Cáncer (AECC APRO 2018). RB and JDS thank MCIN/AEI/https://doi.org/10.13039/501100011033 (PID2020-114178GB-I00, CEX2021-001136-S). Finally, CR, RF and RB acknowledge support from SAF2017-90900-REDT (UBIRed Program, Spain) and COST Action ProteoCure CA20113.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis

  • Serrano Maciá, Marina
  • Simón, Jorge
  • González Rellán, María Jesús
  • Azkargorta, Mikel
  • Goikoetxea-Usandizaga, Naroa
  • Lopitz Otsoa, Fernando
  • Sáenz de Urturi, Diego
  • Rodríguez Agudo, Rubén
  • Lachiondo-Ortega, Sofia
  • Mercado Gómez, María
  • Gutiérrez de Juan, Virginia
  • Bizkarguenaga-Uribiarte, Maider
  • Fernández-Ramos, David
  • Buqué, Xabier
  • Baselli, Guido Alessandro
  • Valenti, Luca
  • Iruzubieta, Paula
  • Crespo, Javier
  • Villa, Erica
  • Banales, Jesus
  • Avila, Matias A.
  • Marin, Jose
  • Aspichueta, Patricia
  • Sutherland, James D.
  • Barrio, Rosa
  • Mayor, Ugo
  • Elortza, Felix
  • Xirodimas, Dimitris
  • Nogueiras Pozo, Rubén
  • Delgado, Teresa
  • Martínez Chantar, María Luz
Objective: Neddylation is a druggable and reversible ubiquitin-like post-translational modification upregulated in many diseases, including liver fibrosis, hepatocellular carcinoma, and more recently, non-alcoholic fatty liver disease (NAFLD). Herein, we propose to address the effects of neddylation inhibition and the underlying mechanisms in pre-clinical models of NAFLD. Methods: Hepatic neddylation measured by immunohistochemical analysis and NEDD8 serum levels measured by ELISA assay were evaluated in NAFLD clinical and pre-clinical samples. The effects of neddylation inhibition by using a pharmacological small inhibitor, MLN4924, or molecular approaches were assessed in isolated mouse hepatocytes and pre-clinical mouse models of diet-induced NAFLD, male adult C57BL/6 mice, and the AlfpCre transgenic mice infected with AAV-DIO-shNedd8. Results: Neddylation inhibition reduced lipid accumulation in oleic acid-stimulated mouse primary hepatocytes and ameliorated liver steatosis, preventing lipid peroxidation and inflammation in the mouse models of diet-induced NAFLD. Under these conditions, increased Deptor levels and the concomitant repression of mTOR signaling were associated with augmented fatty acid oxidation and reduced lipid content. Moreover, Deptor silencing in isolated mouse hepatocytes abolished the anti-steatotic effects mediated by neddylation inhibition. Finally, serum NEDD8 levels correlated with hepatic neddylation during the disease progression in the clinical and pre-clinical models. Conclusions: Overall, the upregulation of Deptor, driven by neddylation inhibition, is proposed as a novel effective target and therapeutic approach to tackle NAFLD
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

HERC Ubiquitin Ligases in Cancer

  • Sala-Gaston, Joan
  • Martinez-Martinez, Arturo
  • Pedrazza, Leonardo
  • Lorenzo-Martín, L. Francisco
  • Caloto, Rubén
  • Bustelo, Xosé R.
  • Ventura, Francesc
  • Rosa, José Luis
© 2020 by the authors., HERC proteins are ubiquitin E3 ligases of the HECT family. The HERC subfamily is composed of six members classified by size into large (HERC1 and HERC2) and small (HERC3–HERC6). HERC family ubiquitin ligases regulate important cellular processes, such as neurodevelopment, DNA damage response, cell proliferation, cell migration, and immune responses. Accumulating evidence also shows that this family plays critical roles in cancer. In this review, we provide an integrated view of the role of these ligases in cancer, highlighting their bivalent functions as either oncogenes or tumor suppressors, depending on the tumor type. We include a discussion of both the molecular mechanisms involved and the potential therapeutic strategies., J.L.R. is supported by the Spanish Ministry of Science and Innovation (BFU2016-80295-R, SAF2017-90900-REDT, and UBIRed). X.R.B. is supported by grants from the Castilla-León Government (CSI252P18, CLC-2017-01), the Spanish Ministry of Science and Innovation (SAF2015-64556-R, RTI2018-096481-B-100) and the Spanish Association against Cancer (GC16173472GARC). X.R.B.’s institution is supported by the Programa de Apoyo a Planes Estratégicos de Investigación de Estructuras de Investigación de Excelencia of the Castilla-León autonomous government (CLC-2017-01). Both Spanish and Castilla-León government-associated funding is partially supported by the European Regional Development Fund. J.S.-G. and A.M.-M. received FPU Fellowships (FPU17/02413 and FPU18/06325, respectively) from the Spanish Ministry of Science, Innovation and Universities.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Regulation of the Ebola Virus VP24 Protein by SUMO

  • Vidal, Santiago
  • Motiam, Ahmed El
  • Seoane, Rocío
  • Preitakaite, Viktorija
  • Hichem Bouzaher, Yanis
  • Gómez-Medina, Sergio
  • San Martín, Carmen
  • Rodríguez, Dolores
  • Rejas, M. Teresa
  • Baz-Martínez, Maite
  • Barrio, Rosa
  • Sutherland, James D.
  • Rodríguez, Manuel S.
  • Muñoz-Fontela, César
  • Rivas, Carmen
Some viruses take advantage of conjugation of ubiquitin or ubiquitin-like proteins to enhance their own replication. One example is Ebola virus, which has evolved strategies to utilize these modification pathways to regulate the viral proteins VP40 and VP35 and to counteract the host defenses. Here, we show a novel mechanism by which Ebola virus exploits the ubiquitin and SUMO pathways. Our data reveal that minor matrix protein VP24 of Ebola virus is a bona fide SUMO target. Analysis of a SUMOylation-defective VP24 mutant revealed a reduced ability to block the type I interferon (IFN) pathway and to inhibit IFN-mediated STAT1 nuclear translocation, exhibiting a weaker interaction with karyopherin 5 and significantly diminished stability. Using glutathione S-transferase (GST) pulldown assay, we found that VP24 also interacts with SUMO in a noncovalent manner through a SIM domain. Mutation of the SIM domain in VP24 resulted in a complete inability of the protein to downmodulate the IFN pathway and in the monoubiquitination of the protein. We identified SUMO deubiquitinating enzyme ubiquitin-specific-processing protease 7 (USP7) as an interactor and a negative modulator of VP24 ubiquitination. Finally, we show that mutation of one ubiquitination site in VP24 potentiates the IFN modulatory activity of the viral protein and its ability to block IFN-mediated STAT1 nuclear translocation, pointing to the ubiquitination of VP24 as a negative modulator of the VP24 activity. Altogether, these results indicate that SUMO interacts with VP24 and promotes its USP7-mediated deubiquitination, playing a key role in the interference with the innate immune response mediated by the viral protein.IMPORTANCE The Ebola virus VP24 protein plays a critical role in escape of the virus from the host innate immune response. Therefore, deciphering the molecular mechanisms modulating VP24 activity may be useful to identify potential targets amenable to therapeutics. Here, we identify the cellular proteins USP7, SUMO, and ubiquitin as novel interactors and regulators of VP24. These interactions may represent novel potential targets to design new antivirals with the ability to modulate Ebola virus replication., Funding at the laboratory of C.R. is provided by Ministry of Science, Innovation and Universities and FEDER (BFU-2017-88880-P). C.R. also acknowledges grants GRC GI-2119 (Xunta de Galicia) and SAF2017-90900-REDT (UBIRed Program). S.V. is a predoctoral fellow funded by Xunta de Galicia. M.B.-M. is a postdoctoral fellow funded by Xunta de Galicia (Consellería de Cultura, Educación e Ordenación Universitaria). A.E.M. is the recipient of a fellowship of the Spanish FPI program. This work was partially funded by the German Center for Infection Research (DZIF TTU 01.702_00 to C.M.-F.). R.B. and J.D.S. acknowledge grants BFU2017-84653-P (MINECO/FEDER, EU), SEV-2016-0644 (Severo Ochoa Excellence Program), 765445-EU (UbiCODE Program), and SAF2017- 90900-REDT (UBIRed Program). C.S.M. acknowledges grant BFU2016-74868-P.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

SUMOylation controls Hu antigen R posttranscriptional activity in liver cancer

  • Lachiondo-Ortega, Sofía
  • Rejano-Gordillo, Claudia María
  • Simón, Jorge
  • Lopitz-Otsoa, Fernando
  • Delgado, Teresa C.
  • Mazan-Mamczarz, Krystyna
  • Goikoetxea-Usandizaga, Naroa
  • Zapata-Pavas, L. Estefanía
  • García-del Río, Ana
  • Guerra, Pietro
  • Peña-Sanfélix, Patricia
  • Hermán-Sánchez, Natalia
  • Al-Abdulla, Ruba
  • Fernández-Rodríguez, Carmen
  • Azkargorta, Mikel
  • Velázquez-Cruz, Alejandro
  • Guyon, Joris
  • Martín, César
  • Zalamea, Juan Diego
  • Egia-Mendikute, Leire
  • Sanz-Parra, Arantza
  • Serrano-Maciá, Marina
  • González-Recio, Irene
  • Gonzalez-López, Monika
  • Martínez-Cruz, Luis Alfonso
  • Pontisso, Patrizia
  • Aransay, Ana M.
  • Barrio, Rosa
  • Sutherland, James D.
  • Abrescia, Nicola G. A.
  • Elortza, Félix
  • Lujambio, Amaia
  • Banales, Jesús M.
  • Luque, Raúl M.
  • Gahete, Manuel D.
  • Palazón, Asís
  • Ávila, Matías A.
  • Marín, José J. G.
  • De, Supriyo
  • Daubon, Thomas
  • Diaz-Quintana, Antonio
  • Díaz-Moreno, Irene
  • Gorospe, Myriam
  • Rodríguez, Manuel S.
  • Martínez-Chantar, María Luz
© 2024 The Author(s). This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)., The posttranslational modification of proteins critically influences many biological processes and is a key mechanism that regulates the function of the RNA-binding protein Hu antigen R (HuR), a hub in liver cancer. Here, we show that HuR is SUMOylated in the tumor sections of patients with hepatocellular carcinoma in contrast to the surrounding tissue, as well as in human cell line and mouse models of the disease. SUMOylation of HuR promotes major cancer hallmarks, namely proliferation and invasion, whereas the absence of HuR SUMOylation results in a senescent phenotype with dysfunctional mitochondria and endoplasmic reticulum. Mechanistically, SUMOylation induces a structural rearrangement of the RNA recognition motifs that modulates HuR binding affinity to its target RNAs, further modifying the transcriptomic profile toward hepatic tumor progression. Overall, SUMOylation constitutes a mechanism of HuR regulation that could be potentially exploited as a therapeutic strategy for liver cancer., This work was supported by grants to M.L.M.-C. from Departamento de Industria del Gobierno Vasco, Spain; Ministerio de Ciencia e Innovación, Spain (grant no. PID2020-117116RB-I00); European Regional Development Fund (ERDF), EU; and CIBERehd, which is funded by Instituto de Salud Carlos III (ISCIII), Spain. M.L.M.-C. and J.S. received funding from Ministerio de Ciencia e Innovación (grant no. RTC2019-007125-1) and ISCIII (grant no. DTS20/00138). M.L.M.-C. and R.M.L. acknowledge Ministerio de Ciencia e Innovación (grant no. RED2022-134397-T). M.L.M.-C. and J.M.B. were awarded with a grant from Fundación la Caixa, Spain (grant no. HR17-00601). M.L.M.-C., J.M.B., M.A.A., and J.J.G.M. acknowledge financial support from Fundación Científica de la Asociación Española Contra el Cáncer (AECC), Spain. M.S.R. recognizes funding from Fondo Sectorial de Investigación SRE - CONACYT, Mexico (grant no. 0280365); Horizon 2020 Research and Innovation Program funded under Marie Skłodowska-Curie Actions, EU (grant no. 765445); and REPÈRE and Programme de Prématuration from Région Occitanie, France. M.G., S.D., and K.M.-M. were supported by the National Institute on Aging (NIA), National Institutes of Health (NIH), US (grant no. Z01-AG000511-23). I.D.-M. is grateful for the grants received from Junta de Andalucía, Spain (grant no. BIO-198, US-1254317, P18-FR-3487, and P18-HO-4091); Ministerio de Ciencia, Innovación y Universidades, Spain (grant no. PGC2018-096049-BI00); and Fundación Ramón Areces, Spain. T.D. acknowledges Fondation ARC, France (grant no. 208084). J.J.G.M. was supported by Junta de Castilla y León, Spain (grant no. SA063P17); Fundación La Marató TV3, Spain (grant no. 201916-31); ISCIII (grant no. PI19/00819); CIBERehd; and ERDF (grant no. OLD-HEPAMARKER). M.A.A. recognizes Gobierno de Navarra, Spain (grant no. GºNa 42/21); Eurorregión Nueva Aquitania-Euskadi-Navarra, Spain; Ministerio de Ciencia e Innovación (grant no. PID2019-104878RB-I00); and CIBERehd. A.P. expresses gratitude to the European Research Council (ERC), EU (grant no. 804236) for their support. M.D.G. received financial support from Junta de Andalucía (grant no. PEMP-0036-2020 and BIO-0139); Ministerio de Universidades, Spain (grant no. FPU20/03957); ISCIII (grant no. PI20/01301), Fundación Sociedad Española de Endocrinología y Nutrición (FSEEN), Spain; CIBERehd; and CIBERobn, which is also funded by ISCIII. J.M.B. acknowledges Euskadi RIS3 (grant no. 2019222054, 2020333010, and 2021333003) and Elkartek programs from Gobierno Vasco (grant no. KK-2020/00008); ISCIII (grant no. PI18/01075, CPII19/00008, and PI21/00922); CIBERehd; PSC Support, UK; AMMF The Cholangiocarcinoma Charity, UK (grant no. EU/2019/AMMFt/001); Horizon 2020 Research and Innovation Program (grant no. 825510); ERDF; and PSC Partners Seeking a Cure, US. A.L. received financial support from the Damon Runyon-Rachleff Innovation Award, US (grant no. DR52-18) and the MERIT Award (R37) from the National Cancer Institute (NCI), NIH (grant no. R37CA230636). F.E. expresses his gratitude to ProteoRed from ISCIII (grant no. PT13/0001/0027) and CIBERehd. N.G.A.A. was funded by Ministerio de Ciencia, Innovación y Universidades (grant no. RTI2018-095700-B-I00). R.B. acknowledges financial support from Gobierno Vasco (grant no. IT1165-19); Ministerio de Economía, Industria y Competitividad, Spain (grant no. SAF2017-90900-REDT); Ministerio de Economía, Industria y Competitividad, ERDF (grant no. BFU2017-84653-P); Ministerio de Ciencia e Innovación (grant no. PID2020-114178GB-I00); and Horizon 2020 funded under Marie Skłodowska-Curie Actions (grant no. 765445-EU). A.M.A. acknowledges CIBERehd. L.A.M.-C. obtained grants from Ministerio de Economía y Competitividad (grant no. CSD2008-00005); Ministerio de Economía, Industria y Competitividad (grant no. BFU2016-77408-R); ISCIII; and EJP RD, EU (grant no. EJPRD19-040). I.G.-R. was supported by Ministerio de Economía, Industria y Competitividad (grant no. BES-2017-080435 ). M.S.-M. is grateful to the AECC, Sede de Bizkaia, Spain for the financial support. J.D.Z. was awarded with a grant from Ministerio de Economía, Industria y Competitividad (grant no. SEV-2016-0644-18-2). C.M. acknowledges Gobierno Vasco (grant no. IT-1264-19) and Ministerio de Ciencia e Innovación (grant no. PID2022-136788OB-I00). A.V.-C. was supported by Ministerio de Educación, Cultura y Deporte, Spain (grant no. FPU016/01513). C.F.-R. thanks Tekniker, Spain and CIC bioGUNE, Spain for financial support. A.G.-d.R. was funded by Bikaintek program from Gobierno Vasco (grant no. 48-AF-W1-2019-00012). N.G.-U. obtained a grant from Gobierno Vasco. T.C.D. expresses gratitude to AECC. J.S. received financial support from CIBERehd. C.M.R.-G. was supported by Ayudas a la Recualificación Margarita Salas from Universidad de Extremadura, Ministerio de Universidades financed by NextGenerationEU., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Constitutive Activation of p62/Sequestosome-1-Mediated Proteaphagy Regulates Proteolysis and Impairs Cell Death in Bortezomib-Resistant Mantle Cell Lymphoma

  • Quinet, Grégoire
  • Xolalpa, Wendy
  • Reyes Garau, Diana|||0000-0002-6124-8953
  • Profitós-Pelejà, Núria|||0000-0001-8923-6025
  • Azkargorta, Mikel
  • Ceccato, Laurie
  • Gonzalez-Santamarta, María
  • Marsal, Maria|||0000-0001-9678-8717
  • Andilla, Jordi
  • Aillet, Fabienne
  • Bosch Albareda, Francesc|||0000-0001-9241-2886
  • Elortza, Felix|||0000-0001-8839-5438
  • Loza-Alvarez, Pablo|||0000-0002-3129-1213
  • Sola, Brigitte|||0000-0001-7278-9651
  • Coux, Olivier|||0000-0001-8455-3849
  • Matthiesen, Rune|||0000-0002-6353-2616
  • Roué, Gaël|||0000-0003-0245-2257
  • Rodriguez, Manuel S.
Protein ubiquitylation coordinates crucial cellular events in physiological and pathological conditions. A comparative analysis of the ubiquitin proteome from bortezomib (BTZ)-sensitive and BTZ-resistant mantle cell lymphoma (MCL) revealed an enrichment of the autophagy-lysosome system (ALS) in BTZ-resistant cells. Pharmacological inhibition of autophagy at the level of lysosome-fusion revealed a constitutive activation of proteaphagy and accumulation of proteasome subunits within autophagosomes in different MCL cell lines with acquired or natural resistance to BTZ. Inhibition of the autophagy receptor p62/SQSTM1 upon verteporfin (VTP) treatment disrupted proteaphagosome assembly, reduced co-localization of proteasome subunits with autophagy markers and negatively impacted proteasome activity. Finally, the silencing or pharmacological inhibition of p62 restored the apoptosis threshold at physiological levels in BTZ-resistant cells both in vitro and in vivo. In total, these results demonstrate for the first time a proteolytic switch from the ubiquitin-proteasome system (UPS) to ALS in B-cell lymphoma refractory to proteasome inhibition, pointing out a crucial role for proteaphagy in this phenomenon and paving the way for the design of alternative therapeutic venues in treatment-resistant tumors.